HORAKOVA, D., P. ROCKOVA, J. JIRCIKOVA, Tomáš DOLEŽAL, M. VACHOVA, P. HRADILEK, M. VALIS, J. SUCHA, A. MARTINKOVA, R. AMPAPA, M. GRUNERMELOVA, I. STETKAROVA, Pavel ŠTOURAČ, J. MARES, Michal DUFEK, E. KMETOVA, J. ADAMKOVA and T. HRNCIAROVA. Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS. MULTIPLE SCLEROSIS AND RELATED DISORDERS. OXFORD: ELSEVIER SCI LTD, 2019, vol. 35, OCT 2019, p. 196-202. ISSN 2211-0348. Available from: https://dx.doi.org/10.1016/j.msard.2019.08.003.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS
Authors HORAKOVA, D. (203 Czech Republic, guarantor), P. ROCKOVA (203 Czech Republic), J. JIRCIKOVA (203 Czech Republic), Tomáš DOLEŽAL (203 Czech Republic, belonging to the institution), M. VACHOVA (203 Czech Republic), P. HRADILEK (203 Czech Republic), M. VALIS (203 Czech Republic), J. SUCHA (203 Czech Republic), A. MARTINKOVA (203 Czech Republic), R. AMPAPA (203 Czech Republic), M. GRUNERMELOVA, I. STETKAROVA, Pavel ŠTOURAČ (203 Czech Republic, belonging to the institution), J. MARES (203 Czech Republic), Michal DUFEK (203 Czech Republic, belonging to the institution), E. KMETOVA (203 Czech Republic), J. ADAMKOVA (203 Czech Republic) and T. HRNCIAROVA (203 Czech Republic).
Edition MULTIPLE SCLEROSIS AND RELATED DISORDERS, OXFORD, ELSEVIER SCI LTD, 2019, 2211-0348.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30103 Neurosciences
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.889
RIV identification code RIV/00216224:14110/19:00111752
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.msard.2019.08.003
UT WoS 000495743000037
Keywords in English Multiple sclerosis; Czech national registry ReMuS; Disease-modifying drugs; Quality of care; Treatment initiation
Tags 14110127, 14110221, 14110516, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 20/1/2020 09:30.
Abstract
Background: : Proper management of multiple sclerosis (MS) requires feedback from clinical practice via registries. Objective: : To introduce the Czech national multiple sclerosis registry, ReMuS, and explore the availability and use of disease-modifying drugs (DMD). Methods: : The analysis focused on patients who started their first DMD, either with first-line or second-line medication and was based on reimbursement criteria set by Czech regulators. Baseline information was used to predict relapses after DMD initiation and to compare patients that started DMD in different years. Results: : A total of 3,328 patients started DMD treatment for MS between 2013 and 2016; 3,203 on first-line and 125 on second-line medication. The proportion of patients starting on second-line drugs increased from 1.8% in 2013 to 4.7% in 2016. The occurrence of a relapse within one year of DMD initiation was significantly related to (1) the Expanded Disability Status Scale (EDSS) score immediately prior to starting DMD and (2) the number of previous relapses. Both parameters were significantly lower in patients starting in later years of the explored interval. Conclusion: : Data from the ReMuS registry highlights improvements made in the management of MS in the Czech Republic. However, a relatively low percentage of patients started treatment using second-line drugs, in contrast to trends in other countries.
PrintDisplayed: 26/4/2024 05:30